AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress
March 28 2022 - 7:35AM
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th
Annual IHPBA World Congress
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or
the “Company”), an immuno-pharma company focused on the research
and development of therapeutics to treat multiple types of cancers,
immune disorders, and viral diseases, including COVID-19, the
disease caused by the SARS-CoV-2 virus, today announced that study
data evaluating the direct effects of Ampligen® (rintatolimod) on
human pancreatic ductal adenocarcinoma (PDAC) cells was accepted
for presentation at the 15th Annual International
Hepato-Pancreato-Biliary Association (IHPBA) World Congress being
held March 30 – April 2, 2022 in New York, NY.
Details of the presentation are as follows:
Title: Rintatolimod: a
potential therapeutic molecule for human pancreatic cancer cells
expressing Toll-Like Receptor 3Presenting Author:
Hassana El Haddaoui, Ph.D., Erasmus University Medical
CenterPoster Number: EP02C-111Presentation
Type: E-Poster PresentationSession: 2C-
Pancreas TumoursDate: Saturday, April 2, 2022
“We are encouraged by the data demonstrated by
Ampligen and its potential to offer beneficial anti-tumor effects
in pancreatic cancer patients. Importantly, the direct effect of
Ampligen on tumor cells and its ability to boost the anti-tumor
immune response via TLR-3 present in immune cells provides the
validation needed to further evaluate its potential to offer
therapeutic effect to pancreatic cancer patients,” commented Thomas
Equels, Chief Executive Officer of AIM.For the study, three PDAC
cell lines (CFPAC-1, MIAPaCa-2, and PANC-1) were treated with
various concentrations of Ampligen and their corresponding vehicle
control. The proliferation and migration effects were examined
using in-vitro assays and the molecular effect was examined by
targeted gene expression profiling. Additionally human PDAC samples
were used to validate the expression of toll-like receptor 3 (TLR3)
by immunohistochemistry.
Dr. El Haddaoui added, “TLR-3 signaling has been
linked to cancer cell survival and migration. Based on these
results, treating pancreatic cancer with Ampligen may have a direct
anti-tumor effect in pancreatic cancer cells expressing TLR-3. We
look forward to further evaluating Ampligen for the treatment of
pancreatic cancer.” Results from the study demonstrated Ampligen
decreased the proliferation and migration ability of CFPAC-1 cells.
In addition, it decreased the proliferation of MIAPaCa-2 cells and
the migration of PANC-1 cells. However, it did not have a dual
effect in MIAPaCa-2 and PANC-1 cells. Interestingly, TLR3 was
highly expressed in CFPAC-1 cells, low expressed in MIAPaCa-2 and
not expressed in PANC-1. Gene expression analysis revealed the
upregulation of interferon-related genes, chemokines, interleukins
and cell cycle regulatory genes. The heterogeneity of TLR3
expression was confirmed in human PDAC samples.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders, and viral diseases,
including COVID-19, the disease caused by the SARS-CoV-2 virus. For
more information, please visit www.aimimmuno.com.
Cautionary Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,”
“expect,” “plan,” “anticipate” and similar expressions (as well as
other words or expressions referencing future events or
circumstances) are intended to identify forward-looking statements.
Many of these forward-looking statements involve a number of risks
and uncertainties. Among other things, for those statements, the
Company claims the protection of safe harbor for forward-looking
statements contained in the PSLRA. While the Company believes that
the results of the study of Ampligen in pancreatic cancer were
positive, significant additional testing will be required. No
assurances can be given as to whether any studies will be
successful or yield favorable data. Additionally, studies and
trials are subject to many factors including lack of regulatory
approval(s), lack of study drug, or a change in priorities at the
institutions sponsoring other trials. There is also the potential
for delays in clinical trial enrollment and reporting because of
the COVID-19 medical emergency. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.
Investor Relations ContactJTC
Team, LLCJenene Thomas 833-475-8247AIM@jtcir.com
Aim Immunotech (LSE:0A4Y)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aim Immunotech (LSE:0A4Y)
Historical Stock Chart
From Apr 2023 to Apr 2024